Company intelligence
Minaris
Advancing Therapies Forward
About Minaris
Minaris is a global cell and gene therapy (CGT) CDMO and a multimodality biosafety testing provider. With more than 25 years of CGT development and manufacturing expertise and more than 40 years in biosafety testing, Minaris combines deep legacy experience with state-of-the-art GMP facilities, and is a fully US-owned organization under new ownership and management, built for today’s evolving therapeutic landscape. Our CDMO team supports CGT innovators from IND through commercial supply, and our testing business delivers GMP analytics, biosafety, viral clearance, and product characterization across CGT and biologics. With 5 global sites on 3 continents, we operate with one mission—to support clinical and commercial therapeutic programs hand in hand with our partners to get more therapies to more patients. We are united by our commitment to excellence, reliability, and a patient-focused purpose as we enable innovators to deliver new therapies and expand patient access worldwide. For more information, visit https://minaris.com. Minaris Advanced Therapies is wholly owned by Altaris, LLC.
Verified activity
Signals from Minaris
7 published signals
Operations & Supply
Minaris Advanced Testing spotlighted the Test Article Receipt (T.A.R.) team in Behind the Scenes to discuss sample management and testing processes.
Reported by Minaris
Presence & Recognition
Minaris will participate in Regenerative Medicine JAPAN 2026, held concurrently with BioJapan 2026, as a company selected under the METI-supported Regenerative CDMO subsidy program.
Reported by Minaris
Presence & Recognition
Minaris is attending the 11th Annual CAR-TCR Summit in Boston from September 15 to 17, 2026, with the Minaris team.
Reported by Heather Durant
Presence & Recognition
Minaris is attending AT2026 in Barcelona next week.
Reported by Cedric Delsemme
Presence & Recognition
Minaris is represented at the 11th Annual CAR-TCR Summit Series on September 16, 2026, where Francesca Vitelli, PhD, VP and Global Head of Process and Analytical Development and Innovation (PADI), will share practical considerations for bridging late-stage clinical manufacturing and commercial supply.
Reported by Minaris
Presence & Recognition
Minaris Advanced Therapies is attending Advanced Therapies Europe with Cedric Delsemme welcoming the opportunity to connect.
Reported by Minaris
Presence & Recognition
Minaris is hosting a Labroots webinar titled From Early Decisions to Late-Stage Success sponsored by Aldevron featuring Luke Kroger, VP of Manufacturing, and Richard Parker-Manuel.
Reported by Minaris